Do you know what immunotherapy is? It is a technique in which a body’s naturally produced T cells are enlisted to fight off cancer. This is a good technique but has one limitation and that is these cells generally lack the firepower to do the job on their own. As a result they need to be modified and reintroduced to the bloodstream to create a real impact. But it seems researchers have stumbled upon a way to rectify this problem. They have discovered a T-cell loaded biogel that can be injected directly into the tumour for a more targeted approach.
This breakthrough came with the development of this biogel developed by scientists at the University of Montreal Hospital Research Centre which remains a liquid while at room temperature. It is made from a biodegradable material derived from the shells of crustaceans and is loaded with a few dozen million T cells rather than the billions needed for Adoptive Cell Therapy.
Adoptive Cell Therapy or ACT involves training the body’s T cells to take the fight to cancerous cells. The current process is an involved process that requires the cells to be collected from the blood and genetically engineered to produce special receptors on their surface, which in turn enables them to recognize particular proteins on the tumour cells. These cells are then cultivated in the laboratory till the population reaches into billions. These cells are then injected back into the bloodstream of the patient. Inside the body, these cells continue to multiply and attack the cancer cells guided by the direction of their new engineered receptor.
[adinserter block=”7″]
As compared to ACT, when the biogel is injected either directly into the tumour or alongside it, it quickly takes the shape of a resistant, cohesive structure which then acts as an on-site breeding ground for cancer-killing T cells behaving like “a cellular reservoir.”
Réjean Lapointe, co-author of the study says, “The T lymphocytes in the gel are functional and can grow for two to three weeks, be released from the gel, and kill the cancerous cells.” In addition to this, the new approach also helps avoid one of the side effects of ACT. A hormone called interleukin-2 is added to the T cells during the engineering to boost their effectiveness, but in high doses it can have a toxic effect. By significantly cutting the quantity of T cells required to neutralize a tumour, the approach can avert the dangers posed by flushing these toxins through bloodstream.
As of now, the gel has only been lab tested working on melanoma and kidney cancer models. The researchers now want to proceed to animals and humans hoping that the success of this technique may open new doors in cancer treatments.
Author: Technology Blog








